IN 1962, in association with
s experimental observations,' Oliver2 reported that a combination of ethyl-p-chlorophenoxyisobutyrate and androsterone reduced serum cholesterol and triglycerides in men with ischemic heart disease. These findings were subsequently confirmed by others,3-5 although later studies have shown that ethyl-p-chlorophenoxyisobutyrate (clofibrate), without androsterone, is equally effective in lowering serum cholesterol and triglycerides in man. 3 6 7 With the exception of reports of Berkowitz8 and Oliver,9 the duration of therapy in the majority of the reported studies documenting the efficacy of clofibrate in lowering serum cholesterol and triglycerides has been 1 year or less, and the number of patients followed by individual investigators has been small. The purpose of the present communication is to present our experience with clofibrate in 45 patients, some of whom have been on continuous therapy for 4 or more years, and to emphasize the type of patient most likely to have a lowering of serum lipids from clofibrate administration.
Methods After a thorough discussion of the purpose and procedures of this investigation, 28 male and 17 female patient volunteers, ranging in age from 27 to 65 years, with persistent elevations of serum cholesterol (>250 mg/100 ml) or glyceride glycerol* (> 15 mg/ 100 ml), were selected for further study. Patients 17 .9 mg/ 100 ml for the clofibrate period was significantly lower than the placebo period (P < 0.02). In the B sequence, the mean glyceride glycerol value of 24.3 mg/100 ml for the clofibrate period was significantly lower than the mean control period value of 45.3 mg/ 100 ml (P < 0.01) and the mean value of 33.4 mg/ 100 ml for the placebo period was significantly higher than the clofibrate period (P < 0.01). The mean glyceride glycerol values for the placebo period in the 15 patients in the B sequence were also compared with the mean of 22.0 mg/100 ml for their subsequent 3 months of clofibrate, and significant lowering with clofibrate was again noted (P < 0.05). No significant weight changes occurred during the crossover study. This type of experimental design also minimizes the influence of weight or dietary changes should they occur, and thus further validates the drug as the factor responsible for the reduction in serum lipids.
Long-Term Effects
The long-term effects of clofibrate on the serum cholesterol and triglycerides are summarized in tables 1 and 2. The data are derived from the 35 patients in the crossover study with the zero time for this group being completion of the crossover study and from 10 other patients who were entered into this study after completion of control period only. creasing number of patients in the longer treatment periods is primarily the result of the patients being entered into the study at different times. Also, two patients died and three moved from the vicinity during the early phases of the study.
The effect of clofibrate on the mean serum cholesterol calculated from all absolute values obtained during each 3-month period is illustrated in table 1. A significant reduction in serum cholesterol followed during clofibrate administration for the first 12 months of treatment whether the change was calculated as an absolute value or percentage for each patient. Thereafter, the reduction was not statistically significant, although the percentage of patients with a reduction of 15% or more in concentration of serum cholesterol was reasonably stable throughout the study. The effect of clofibrate on the mean serum triglycerides for each treatment period is illustrated in table 2. A significant and persistent reduction in serum triglycerides was noted throughout the study and 75 to 80% of all patients with elevated triglycerides had at least a 25% reduction following clofibrate administration.
The correlation between the individual mean control serum glyceride glycerol values and the individual mean absolute change in glyceride glycerol for the 38 patients completing 6 months of treatment with clofibrate is plotted in figure 2 . The magnitude of reduction following clofibrate is closely correlated with the control glyceride glycerol value (r = 0.870). The one patient with a mean control glyceride glycerol of 98 mg/ 100 ml having a reduction of only 14 mg/ 100 ml following clofibrate was an obese male who was 50 pounds over his ideal weight.
A similar plot of the cholesterol values from the same patients is shown in figure 3 . The unbroken line represents the correlation for all patients and there is an overall tendency for a greater reduction in serum cholesterol with higher control serum cholesterol values (r= 0.539). If these patients were subdivided into those with glyceride glycerol values above and below 25 mg/ 100 ml, those patients with serum glyceride glycerol values above 25 However, the group with initial glyceride glycerol levels of >25 mg/ 100 ml had a persistent reduction in serum cholesterol throughout the study. Since the longer periods of observation contain more potential nonresponders, our results cannot be simply interpreted to mean that clofibrate is ineffective after 1 year of administration.
The recent classification of patients with hyperlipidemias according to the lipoprotein patterns described by Fredrickson and associates20 appears to be of value in predicting a patient's response to clofibrate. Serum lipoprotein patterns were not obtained on a sufficient number of our patients to warrant our using this classification, the patients being arbitrarily divided into those with serum glyceride glycerol levels above and below 25 mg/ 100 ml to define those patients with hypercholesteremia most likely to respond to clofibrate. Patients 
